It could be years before a cell therapy from Nkarta reaches autoimmune disease patients in the market, but CEO Paul Hastings still thinks about the impact of pharmaceutical tariffs here ...
AI has quickly been moving through the pharmaceutical industry, where professionals are seeing clear value – from shortening the drug development timeline to matching patients to more ...
Sanofi is shelling out $1.15 billion to acquire Vicebio, a startup with a pipeline of respiratory vaccine candidates and a platform technology that will support the pharmaceutical giant’s ...
Biologic medicines are making inroads into chronic obstructive pulmonary disease (COPD), with two blockbuster antibodies expanding their FDA-approved uses to this lung disorder in the ...
Weight management remains a popular topic in our society. This doesn’t come as a surprise, as reports indicate that obesity affects nearly 43% of adults in the U.S. alone. Obesity is ...
For the third time this year, a patient treated with a Sarepta Therapeutics gene therapy has died, a revelation that comes as the company tries to earn back patient and investor trust ...
Sarepta Therapeutics’ report of a second fatality this year in a patient dosed with its Duchenne muscular dystrophy gene therapy raised the prospect it might have to pull the product from ...
A drug that AstraZeneca singled out as one of its key potential revenue growth drivers in the next decade has failed a pivotal study in light chain amyloidosis, a rare disease with few ...
A Hengrui Pharma obesity drug designed to hit two targets led to an average of nearly 18% weight loss in a pivotal study, paving the way for a regulatory submission in China, where the ...
A Bayer drug the company frames as key to growing its cardiovascular portfolio has expanded its FDA approval to a type of heart failure, a new indication that keeps this pill on the path ...
The mounting conversations around compounded GLP-1 medications aren’t just about science or safety. Rather, lawsuits and corporate power plays have had massive influence on how these ...
When the FDA turns down a drug application, it has historically been up to the drug company to reveal it. These FDA complete response letters, or CRLs, haven not been considered public ...